Clinical Trial Update: Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and modulation of adaptive immunity by Iscador Qu mistletoe extract in patients with advanced cancers treated with immune checkp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Iscador Qu Viscum Album Extract (Viscum album extract)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Advanced Solid Tumor | Phase 4 | Status: RECRUITING